Ontology highlight
ABSTRACT:
SUBMITTER: Corey SJ
PROVIDER: S-EPMC6111823 | biostudies-other | 2018 Sep
REPOSITORIES: biostudies-other
Corey Seth J SJ Jha Jyoti J McCart Elizabeth A EA Rittase William B WB George Jeffy J Mattapallil Joseph J JJ Mehta Hrishikesh H Ognoon Mungunsukh M Bylicky Michelle A MA Summers Thomas A TA Day Regina M RM
Journal of cellular and molecular medicine 20180704 9
Allogeneic stem cell transplantation is currently the only curative therapy for primary myelofibrosis (MF), while the JAK2 inhibitor, ruxolitinib. Has been approved only for palliation. Other therapies are desperately needed to reverse life-threatening MF. However, the cell(s) and cytokine(s) that promote MF remain unclear. Several reports have demonstrated that captopril, an inhibitor of angiotensin-converting enzyme that blocks the production of angiotensin II (Ang II), mitigates fibrosis in h ...[more]